Tenmile’s Post

🚨 Breaking: InterVene, Inc. Secures $13M Series A Funding to Revolutionize Deep Vein Treatment 💥 InterVene, a Redwood City-based medtech leader, is pushing boundaries in chronic venous disease treatment. Here’s how they’re advancing vascular health with the recent Series A round: What’s Driving This Innovation: • Lead by Treo Ventures & RiverVest Venture Partners: Funding secured for final Recana catheter system development, clinical trials, and U.S. regulatory submission. 💰 • New Leadership Addition: Treo Ventures' Brad Vale joins InterVene’s Board, bringing deep expertise in medtech scaling. Why Recana is a Game-Changer: • Precision in Deep Vein Treatment: Recana is designed for recanalization in chronic deep vein obstructions, especially where conventional solutions fall short. • Seamless for Specialists: Uses Fluoroscopy/IVUS-guided techniques, aligning with methods already familiar to vascular specialists. ⚙️ Built on a Strong Foundation: Developed with support from the Stanford Biodesign Fellowship and residency at the Fogarty Institute, InterVene’s team of interventional experts is set to lead in deep venous care. The path to initial commercialization and post-market research is set, positioning InterVene as a significant player in venous disease innovation. 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs ♻️ Repost if you think this insight is worth sharing!

As a father, husband, son, and scientist I dream of a world where no neurological disease is beyond our reach, where we don't shy away from targets because they seem too risky. A world where every neurological disease, no matter how tough, is druggable. Today, with the unveiling of Montara Therapeutics, Inc., I hope to contribute to making that dream a reality.  At my previous company, Mitokinin, we worked for nearly a decade to develop a potential disease-modifying treatment for Parkinson's disease. During that process, I learned how difficult it is to generate safe and effective drugs for many of the neurological diseases that millions suffer from worldwide. After Mitokinin was acquired last fall, I knew that I wanted to start a new company to address some of the other tough-to-drug neurological indications, including Alzheimer's disease, brain cancers, and neuropsychiatric indications. When Kevan Shokat, who was my Ph.D. supervisor University of California, San Francisco and scientific co-founder of Mitokinin, came to me with new research from his lab suggesting a pharmacological mechanism to block drugs from working in the periphery, thereby mitigating their adverse side effects, I immediately recognized the impact this could have, not for the treatment of just one or two diseases, but across nearly all neurodegenerative and neurological diseases and brain cancer.  Together, with the help of our other scientific co-founders, Martin Kampmann and Thomas Südhof, a highly experienced team of advisors, as well as nine stellar employees from Mitokinin, we formed Montara Therapeutics to progress this groundbreaking research from bench to bedside, developing safer and more efficacious treatments for various diseases of the brain. Today, we’re thrilled to announce the funding of our seed round. With support from top-tier investors, including SV Dementia Discovery Fund (DDF), Two Bear Capital, KdT Ventures, and Dolby Family Ventures, I believe we have the right ingredients to accomplish our mission, and I’m very excited for what the future has in store for Montara, but most importantly, for patients We look forward to sharing more details in the months to come. Follow Montara Therapeutics, Inc. to stay updated on our progress. Thanks to Amber Tong and Endpoints News for the exclusive!

🌍 As mentioned earlier this week, Aktiia is now #transatlantic. 🚀 🛑 The time when our loved ones die because their high BP is unscreened or unmonitored is coming to an end. Treating #hypertension is generally straightforward with the available treatments, but it's a fact that oscillometric cuffs have failed in the screening and monitoring phases. 🔧 We are here to create the inflection point. 🎉 Just starting, and we already have over 100,000 users of our continuous BP monitor. We won't stop until we reach out to the 630 million people our regulatory approvals already allow us to! 📈 Basic principle: if something doesn't work, fix it! 🔗 Check out more here: https://lnkd.in/e6fVteFv redalpine Translink Capital Molten Ventures Khosla Ventures 415 Capital Verve Ventures

“What led us to apply again was that constant need to grow and learn more,” says Barbara Oliveira Co-Founder & Chief Clinical Officer at Luminate Medical. Galway-based start-up Luminate Medical is pioneering wearable medical devices that mitigate painful chemotherapy-induced side effects such as hair loss and peripheral neuropathy. These cutting-edge solutions are designed to improve the quality of life for cancer patients by enabling treatment from the comfort of their homes, reducing the physical emotional toll of chemotherapy. In 2022, Luminate Medical participated in EIT Health’s Catapult programme, earning the prestigious Audience Choice Award. We’re proud to have supported their journey as they continue to revolutionise cancer care on a global scale. Through the Catapult programme, they were able to refine their pitch, expanded their investor network, and further advanced their mission to improve cancer patients' quality of life. Learn more about Luminate Medical’s journey: https://lnkd.in/deYE4E-X #CancerCare #Innovation #Healthcare #Startups #EITHealth #MedicalDevices Aaron Hannon Martin OHalloran Marc Butterly

Cardiovascular diseases remain a leading cause of mortality worldwide. We explore 10 startups pioneering medical devices for cardiology that could transform heart care and improve patient outcomes 🧠🤝 https://lnkd.in/g2WNQNKz Keep up the good work 🫶 3.LIFE Pacertool AS InCarda Therapeutics Restore Medical Prometheus Med Tech.AI Recor Medical Shockwave Medical Vectorious Medical Technologies Cardiawave FineHeart Ps. To make this story even more valuable for the new comers, we added a dash of advice on how to start a MedTech journey. 🚀

🎉 Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) invests $10M in StartUp Health company Alamar Biosciences to advance precision medicine in Alzheimer's disease! ➡️ https://ow.ly/Xx8V50UCfgX #HealthTransformer #HealthMoonshot #AlzMoonshot #ADDF #DxA

many of the most impactful drugs for patients suffering from neuropsychiatric disease have brutal side effects, leaving patients with a tough choice between suffering intolerable toxic effects vs managing their disease without medication. Montara Therapeutics, Inc. is addressing this problem with a target-agnostic platform for two-drug combinations: an active, brain-penetrant drug combined with a peripheral blocker that counters toxic effects of the drug in the rest of the body. the concept isn't new - a similar strategy is employed by carbidopa/levodopa in Parkinson's, and Karuna's muscarinic agonist combo which was acquired by BMS for $14B last year. Montara is supercharging this strategy, building a more general approach that works across many different classes of targets and diseases. pumped to back Nicholas Hertz, Ph.D, Rishi Rakhit, Zachary Hill, Randall Chin, PhD Max Lebovitz, alongside SV Dementia Discovery Fund (DDF), Two Bear Capital, and Dolby Family Ventures. feature in endpoints: https://lnkd.in/eQPK3pj3 press release: https://lnkd.in/ezUx-USV

Flow Medical has announced the closing of an oversubscribed US$5 million seed funding round to accelerate the development and launch of its pulmonary embolism device. Read more: https://lnkd.in/edhyrWwQ

One of the largest US digital therapeutics companies, Hinge Health is going IPO - this is a big validation for the business of digital therapeutics and its future. Have been tracking Hinge health for the last 3 years and always found it to be a very focused and interesting play on delivering virtual physical therapy with a sole focus on digital musculoskeletal care (MSK). With growing urbanization and the rapid rise in desk jobs, we have millions suffering from back, neck, shoulder or other musculoskeletal pain. Hinge Health observed this early and built out an entire digital clinic portfolio focusing on solving this. It takes individuals through personalized programmes (delivered through data and sensors) which are gamified physical exercise programmes based on their requirements - all happening digitally. In terms of traction, Hinge Health's platform is used by over 1 million patients and is covered by over 50 health plans along with 1700 organizations using it for their employees wellness. It also successfully raised ~1 B USD for accelerating its growth and reach. Hinge health stands out as a good example of the evolution of the digital therapeutics players. At Evernile, we are very bullish on such digital therapeutics companies which are extensively building for a particular clinical area - makes them more clinically focused and helps in verticalization and personalization. If you are building in this space, would love to chat! PC: Hinge Health website.

CergenX is pleased to announce the first step in forming its advisory board with the appointment of Neil Campbell as an advisor. Neil brings over 30 years of expertise in the MedTech industry, with a specialised focus on products aimed at diagnosing and treating newborn brain conditions since 2003. Most recently, Neil served as CEO of Inspiration Healthcare Group PLC, where he successfully led the company through a period of significant growth and innovation. As an advisor to the Board, Neil will provide strategic direction on the commercialisation of Wave, CergenX’s flagship device. Wave leverages CergenX’s cutting-edge AI algorithms to identify newborns most at risk of brain injury with speed and precision. Jason Mowles, CEO of CergenX, said: “We are delighted to welcome someone of Neil’s calibre to the advisory board. His deep experience in scaling startups and bringing groundbreaking neonatal technologies to market will be invaluable as we advance to the next phase of our journey.” Neil Campbell commented: “I have been consistently impressed by the progress CergenX has made, as well as the passion and expertise of its team. I’m excited to support the commercial rollout of this transformative technology, which has the potential to redefine the future of newborn brain health.” #MedTechInnovation #AiForGood #AIinHealthcare